BMC Neurol

1. BUDUMURI VSK, G AK, Murugadoss H, Arun V, et al
   Patient-reported health utility in adults with myasthenia gravis: a systematic review and meta-analysis of EQ-5D outcomes.
   BMC Neurol. 2026 Jun 2. doi: 10.1186/s12883-026-05033.
   

   >> Share

   
   

   
   Intern Med

2. CHUNG SW, You JL, Ha YJ
   Immunoglobulin G4-related Disease with Solitary Nasopharynx Involvement Mimicking Nasopharyngeal Tumor.
   Intern Med. 2026;65:1566-1571.
   

   >> Share

   
   
3. SATO I, Onaka R, Fujiwara S, Hirasawa A, et al
   Reversible Cerebral Vasoconstriction Syndrome Associated with Autoimmune Hemolytic Anemia.
   Intern Med. 2026 May 30. doi: 10.2169/internalmedicine.7284.
   

   >> Share

   
   

   
   J Nephrol

4. PRAKASH TS, Kamat N, Janardhanan JJ
   Immune complex-mediated membranoproliferative glomerulonephritis following scabies infestation in a child: a rare association.
   J Nephrol. 2026 Jun 5:aajag062. doi: 10.1093.
   

   >> Share

   
   

   
   J Neurol

5. BET MDA, Helmlinger B, Broeders TAA, Hechenberger SMC, et al
   Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis.
   J Neurol. 2026;273:354.
   

   >> Share

   
   
6. BERGSLAND N, Burnham A, Dwyer MG, Bartnik A, et al
   Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.
   J Neurol. 2026;273:364.
   

   >> Share

   
   
7. TEDONE N, Preziosa P, Pagani E, Meani A, et al
   Structural MRI signature of late- versus adult-onset multiple sclerosis: a multiparametric study.
   J Neurol. 2026;273:360.
   

   >> Share

   
   
8. HOWARD JF JR, Sacca F, Hoffmann S, Attarian S, et al
   Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double?blind, placebo?controlled, phase 3 trial (ADAPT).
   J Neurol. 2026;273:363.
   

   >> Share

   
   

   
   J Rheumatol

9. JAMES EA
   From Mouth to Joint: Citrullinated Bacteria in Driving Synovial Autoimmunity.
   J Rheumatol. 2026 Jun 1:jrheum.2026-0410. doi: 10.3899/jrheum.2026-0410.
   

   >> Share

   
   

   
   Lancet

10. LEE PJ, Wong MG
    Endothelin antagonism in IgA nephropathy: promise ahead of proof?
    Lancet. 2026 Jun 4:S0140-6736(26)01094-9. doi: 10.1016/S0140-6736(26)01094.
    

    >> Share

    
    
11. HEERSPINK HJL, Jardine MJ, Kohan DE, Lafayette R, et al
    Atrasentan in patients with IgA nephropathy (ALIGN): final 2.5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2026 Jun 4:S0140-6736(26)00960-8. doi: 10.1016/S0140-6736(26)00960.
    

    >> Share

    
    

    
    Mult Scler

12. BENALLEGUE N, Rollot F, Iaffaldano P, Lucisano G, et al
    A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.
    Mult Scler. 2026 Jun 1:13524585261446829. doi: 10.1177/13524585261446829.
    

    >> Share

    
    
13. CORREALE J, Marrodan M, Piedrabuena MA, Soman K, et al
    Microbiome-derived metabolites from vitamin B2 and B9 pathways modulate MAIT cells from multiple sclerosis patients.
    Mult Scler. 2026 Jun 1:13524585261447695. doi: 10.1177/13524585261447695.
    

    >> Share

    
    
14. LAULE C, Cohen-Adad J, Witt AA, De Luca GC, et al
    Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities.
    Mult Scler. 2026 Jun 1:13524585261444600. doi: 10.1177/13524585261444600.
    

    >> Share

    
    
15. POSER PL, Gisevius B, Tokic M, Fisse AL, et al
    Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.
    Mult Scler. 2026 Jun 1:13524585261446846. doi: 10.1177/13524585261446846.
    

    >> Share

    
    
16. SANDESJO F, McKay KA, Fink K, Piehl F, et al
    Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study.
    Mult Scler. 2026 May 31:13524585261448789. doi: 10.1177/13524585261448789.
    

    >> Share

    
    
17. TALLANTYRE EC, Planchon SM, Howard H, Mays J, et al
    Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).
    Mult Scler. 2026 May 31:13524585261449988. doi: 10.1177/13524585261449988.
    

    >> Share

    
    
18. SARASTE M, Nikkila T, Matilainen M, Hamalainen P, et al
    TSPO-PET-measurable neuroinflammation associates with information processing speed decline in multiple sclerosis.
    Mult Scler. 2026 May 31:13524585261446839. doi: 10.1177/13524585261446839.
    

    >> Share

    
    

    
    N Engl J Med

19. FERVENZA FC, Hou FF, Hao CM, Kirsztajn GM, et al
    Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.
    N Engl J Med. 2026 Jun 5. doi: 10.1056/NEJMoa2602678.
    

    >> Share

    
    

    
    Neurology

20. YAO Y, Li Y, Liu J, Ji Z, et al
    Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment.
    Neurology. 2026;106:e218120.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share